The U.S. Food and Drug Administration has approved expanded use of Amgen's drug, Uplizna, to help reduce the risk of flares ...
Inebilizumab-cdon (Uplizna; Amgen) was approved as the first and only treatment for immunoglobulin G4–related disease ...
Inebilizumab-cdon was previously approved by the FDA for neuromyelitis optica spectrum disorder (NMOSD) in adults who are ...
Advances Amgen’s Leadership in CD19 Directed, B-Cell Depletion Therapies for Serious Autoimmune Diseases Including NMOSD, IgG4-RD and gMG THOUSAND OAKS, CA, USA I April 3, 2025 I Amgen (NASDAQ:AMGN) ...
Amgen AMGN announced that the FDA has approved its rare disease drug Uplizna (inebilizumab) for a new indication. The regulatory body has now approved Uplizna for the treatment of adults living with ...
The Food and Drug Administration (FDA) has approved Uplizna ® (inebilizumab-cdon) for the treatment of immunoglobulin G4-related disease (IgG4-RD) in adult patients.
The FDA on Thursday gave the green light to Uplizna in IgG4-related disease, making it the first and only approved treatment ...
Acquired as part of its $27.8 billion takeover of Horizon Therapeutics in 2023, CD19-targeting Uplizna (inebilizumab) is the ...
Others fired included staffers working on the Right to Try Act -- a law passed in President Trump's first term that aims to ...
The US Food and Drug Administration (FDA) has approved Uplizna (inebilizumab-cdon) as the first and only treatment for adults ...
These are data to week 26 on the monoclonal antibody and antineoplastic agent; data out to week 52 of the MINT trial will be ...
Amgen (NASDAQ:AMGN) announced today that the U.S. Food and Drug Administration (FDA) has approved UPLIZNA as the first and onl ...